Andere Kunden interessierten sich auch für
![Myelodysplastic Syndromes, an Issue of the Clinics in Laboratory Medicine]( "Myelodysplastic Syndromes, an Issue of the Clinics in Laboratory Medicine")
Myelodysplastic Syndromes, an Issue of the Clinics in Laboratory Medicine106,99 €![Overgrowth Syndromes]( "Overgrowth Syndromes")
Overgrowth Syndromes171,99 €![The Molecular Biology of Down Syndrome]( "The Molecular Biology of Down Syndrome")
The Molecular Biology of Down Syndrome166,99 €![The Molecular Biology of Down Syndrome]( "The Molecular Biology of Down Syndrome")
The Molecular Biology of Down Syndrome183,99 €![Management of Prader-Willi Syndrome]( "Management of Prader-Willi Syndrome")
Management of Prader-Willi Syndrome192,99 €![Human Physiology Annual Volume 2024]( "Human Physiology Annual Volume 2024")
Human Physiology Annual Volume 2024135,00 €![Hypoxia and Anoxia]( "Hypoxia and Anoxia")
Hypoxia and Anoxia91,99 €
This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.